Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 1/2013

01-01-2013 | Original Paper

Substance Use Predictors of Poor Medication Adherence: The Role of Substance Use Coping Among HIV-Infected Patients in Opioid Dependence Treatment

Authors: Adam Gonzalez, Matthew J. Mimiaga, Jared Israel, C. Andres Bedoya, Steven A. Safren

Published in: AIDS and Behavior | Issue 1/2013

Login to get access

Abstract

Many HIV-infected injection drug users (IDUs) continue to use illicit substances despite being in substance use treatment. Substance use is associated with non-adherence to HIV medications; however underlying mechanisms regarding this relation are understudied. The current investigation examined the role of substance use coping in terms of the relation between substance use and HIV medication adherence. Participants were 121 HIV-infected IDUs (41 % female, M age = 47, SD = 7.1) in opioid dependence treatment. Participants completed self-report questionnaires, were administered clinical interviews and oral toxicology screens, and used a medication-event-monitoring-system cap to assess 2 week HIV medication adherence. The use of cocaine and multiple substances were significantly related to decreased medication adherence. Substance use coping mediated these associations. Findings highlight the importance of assessing, monitoring, and targeting ongoing substance use, and ways to increase positive coping for HIV-infected IDUs in substance use treatment to aid in HIV medication adherence.
Literature
1.
de Olalla PG, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30:105–10.
2.
Low-Beer S, Yip B, O’Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360–1.PubMed
3.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed
4.
Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection. J Am Med Assoc. 2010;304:321–33.CrossRef
5.
Kuritzkes DR. HIV drug resistance: new insight and updated practices. Physicians’ Res Netw. 2004;9:9–13.
6.
Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008;22:75–82.PubMedCrossRef
7.
Castilla J, del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40:96–101.PubMedCrossRef
8.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.PubMedCrossRef
9.
Quinn TC, Wawer MJ, Sewnkanbo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type-1. N Engl J Med. 2000;342:921–9.PubMedCrossRef
10.
Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81–8.PubMedCrossRef
11.
Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV medication treatment. Curr HIV/AIDS Rep. 2011;8:223–34.PubMedCrossRef
12.
Spire B, Lucas GM, Carrier MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262–70.PubMedCrossRef
13.
Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: swiss HIV cohort study. J Acquir Immune Defic Syndr. 2010;54:197–203.PubMed
14.
Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26:195–205.PubMedCrossRef
15.
Weber R, Huber M, Rickenbach M, et al. Uptake of and virological response to antiretroviral therapy among HIV-infect former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med. 2009;10:407–16.PubMedCrossRef
16.
Cohn SE, Jiang H, McCutchan JA, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23:775–85.PubMedCrossRef
17.
Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11:185–94.PubMedCrossRef
18.
Abrams DB, Niaura RS. Social learning theory of alcohol use and abuse. In: Blane H, Leonard K, editors. Psychological theories of drinking and alcoholism. New York: Guilford Press; 1987. p. 131–78.
19.
Shiffman S, Wills TA. Coping and cessation of substance use. In: Shiffman S, Wills TA, editors. Coping and substance use. New York: Academic Press; 1985. p. 221–40.
20.
Gonzalez JS, Batchelder AW, Psaros C, Safren S. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181–7.PubMed
21.
Waldrop-Valverde D, Valverde E. Homelessness and psychological distress as contributors to antiretroviral adherence in HIV-positive injection drug users. AIDS Patient Care STDs. 2004;19:226–334.
22.
Power R, Koopman C, Volk J, et al. Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected patients. AIDS Patient Care STDs. 2003;17:245–52.PubMedCrossRef
23.
Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968–77.PubMed
24.
Liu H, Miller G, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41:315–22.PubMedCrossRef
25.
Llabre MM, Weaver KE, Duran RE, Antoni MH, McPherson-Baker S, Schneiderman N. A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults. AIDS Patient Care STDs. 2006;20:701–11.PubMedCrossRef
26.
Safren SA, O’Cleirigh CO, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1–10.PubMedCrossRef
27.
Safren SA, O’Cleirigh CM, Bullis JR, Otto MS, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80:404–15.PubMedCrossRef
28.
Stirratt MJ, Remien RH, Smith A, et al. The role of HIV serostatus disclosure in antiretroviral medications adherence. AIDS Behav. 2006;10:483–93.PubMedCrossRef
29.
Carver CS. You want to measure coping but your protocol is too long: consider the Brief COPE. Int J Behav Med. 1997;4:92–100.PubMedCrossRef
30.
Bottonari KA, Safren SA, McQuaid JR, Hsiao C, Roberts JE. A longitudinal investigation of the impact of life stress on HIV treatment adherence. J Behav Med. 2010;33:486–95.PubMedCrossRef
31.
Kelly BC, Bimbi DS, Izienicki H, Parsons JT. Stress and coping among HIV-positive barebackers. AIDS Behav. 2009;13:792–7.PubMedCrossRef
32.
Gay C, Portillo CJ, Kelly R, et al. Self-reported medication adherence and symptom experience in adults with HIV. J Assoc Nurses AIDS Care. 2011;22:257–68.PubMedCrossRef
33.
Hinkin CH, Hardy DJ, Mason KL, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18:S19–25.PubMedCrossRef
34.
Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8:277–87.PubMedCrossRef
35.
Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18:248–57.PubMedCrossRef
36.
Baron R, Kenny D. The moderator-mediator distinction in social psychological research: conceptual strategic and statistical considerations. J Pers Soc Psychol. 1986;51:1173–82.PubMedCrossRef
37.
Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. In: Leinhardt S, editor. Sociological Methodology. Washington: American Sociological Association; 1982. p. 290–312.
38.
Hessol NA, Weber KM, Holman S, et al. Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health. 2009;18:1627–37.CrossRef
39.
Gonzalez A, Vujanovic AA, Johnson KA, Leyro TM, Zvolensky MJ. The role of mindful attention in regard to the relation between negative affect reduction outcome expectancies and emotional vulnerability among adult daily smokers. Cogn Ther Res. 2009;33:645–56.CrossRef
40.
Johnson KA, Zvolensky MJ, Marshall EC, Gonzalez A, Abrams K, Vujanovic AA. Linkages between cigarette smoking outcome expectancies and negative emotional vulnerability. Addict Behav. 2008;33:1416–24.PubMedCrossRef
41.
Blashill AJ, Perry N, Safren SS. Mental health: a focus on stress, coping, and mental illness as it related to treatment retention, adherence, and other health outcomes. Curr HIV/AIDS Rep. 2011;8:215–22.PubMedCrossRef
42.
Stone AA, Shiffman S. Ecological momentary assessment (EMA) in behavioral medicine. Ann Behav Med. 1994;16:99–202.
43.
Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21:4–9.PubMedCrossRef
44.
Palepu A, Milloy M, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected drug users. J Urban Health. 2011;88:545–55.PubMedCrossRef
45.
Sharpe TT, Lee LM, Nakashima AK, et al. Crack cocaine use and antiretroviral treatment among HIV-infected Black women. J Community Health. 2004;29:117–27.PubMedCrossRef
46.
Baum M, Rafie C, Lai S, et al. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50:93–9.PubMedCrossRef
47.
Duncan R, Shapshak P, Page JB, et al. Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV-infected African American women. Front Biosci. 2007;12:1488–95.PubMedCrossRef
48.
McLellan TA, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis. 1980;168:26–33.PubMedCrossRef
Metadata
Title
Substance Use Predictors of Poor Medication Adherence: The Role of Substance Use Coping Among HIV-Infected Patients in Opioid Dependence Treatment
Authors
Adam Gonzalez
Matthew J. Mimiaga
Jared Israel
C. Andres Bedoya
Steven A. Safren
Publication date
01-01-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0319-6

Other articles of this Issue 1/2013

AIDS and Behavior 1/2013 Go to the issue

Original Paper

Barriers to Medication Adherence in Behaviorally and Perinatally Infected Youth Living with HIV

Original Paper

Provider-patient Adherence Dialogue in HIV Care: Results of a Multisite Study

Original Paper

Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children

Original Paper

Personal HIV Knowledge, Appointment Adherence and HIV Outcomes

Original Paper

Oral Adherence Monitoring Using a Breath Test to Supplement Highly Active Antiretroviral Therapy

Original Paper

Communicating HIV Status in Sexual Interactions: Assessing Social Cognitive Constructs, Situational Factors, and Individual Characteristics Among South African MSM
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits